Abiopharma

🔍 Ellingson Alan Wayne (Executive)

Company: DraftKings Inc. (DKNG)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 4,311 shares of Class A Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 163,712.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,438 shares of Class A Common Stock at $23.0 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 162,274.00 | transaction_form_type: 4
• Sold 4,311 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,481.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2

Footnotes:

• F1: No shares of Class A Common Stock were transferred or sold upon the vesting of the restricted stock units ("RSUs") other than to the Issuer to satisfy withholding taxes. The Reporting Person received the net of the 4,311 shares of Class A Common Stock underlying the RSUs listed in Table II, and 1,438 shares of Class A Common Stock withheld by the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F2: On May 1, 2024, the Reporting Person was granted 68,963 RSUs vesting quarterly over four (4) years from May 1, 2024.